Clinical Trial Update: Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update describing safety, tolerability, and pharmacodynamic profile of oral 2101 in secondary Raynaud's Disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Raynaud Disease

Drugs mentioned

• 2101

Snippet

Sponsor: Response Pharmaceuticals | Conditions: Raynaud's Disease | Phase 2 | Status: COMPLETED